17th June 2024
There was an intriguing line in last week’s Labour Party manifesto. It came early in the piece, in just the second sentence. It described…
Read more
3rd June 2024
Currencies are like referees. When you don’t notice them, they are doing a good job. So it is with encouraging economic portents that the…
Read more
6th May 2024
Economies thrive on the individual pursuit of personal profit and purpose in return for taking risk. Risk as entrepreneurs mortgage the family home. Risk…
Read more
15th April 2024
In the latest episode of Conversations with Panmure Gordon, Daniel Koller, Head of Investment team at BB Biotech joins Julie Simmonds, Healthcare Analyst to…
Read more
8th April 2024
Panmure Gordon is thrilled to announce that it has acted as Nominated Adviser, Sole Bookrunner and Broker on the successful £14.45m IPO of European…
Read more
24th March 2024
The last week has seen considerable flux in the cost of money. Enthusiasm for cheaper money in the world’s largest economy, the US, helped…
Read more
26th February 2024
Artificial Intelligence (AI) is at the very forefront of investors minds. AI made a significant contribution to Microsoft’s record $62 billion earnings in the…
Read more
18th January 2024
Panmure Gordon is pleased to announce that it has acted as Rule 3 Adviser, Nominated Adviser and Financial Adviser to Velocys plc in relation…
Read more
10th January 2024
In the latest episode of Conversations with Panmure Gordon, Steven Levin, Chief Executive Officer at Quilter joins Simon French, Chief Economist and Head of…
Read more
21st November 2023
Panmure Gordon is delighted to announce the completion of a £146.6m Accelerated Bookbuild for Sirius Real Estate. Panmure Gordon acted as Joint Bookrunner…
Read more
17th November 2023
Panmure Gordon is pleased to announce its appointment as Joint Corporate Broker to International Personal Finance (IPF.L/Mkt Cap £268m). IPF is a global…
Read more
14th November 2023
Panmure Gordon is delighted to announce that it has acted as Rule 3 Adviser, Financial Adviser, Nominated Adviser and Sole Broker to Allergy Therapeutics…
Read more